9 search results for “midazolam” in the Public website
Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery
Promotor: C.A.J. Knibbe, Co-promotores: H.P.A. van Dongen, B. van Ramshorst
The impact of obesity on the pharmacokinetics of drugs in adolescents and adults
Promotores: C.A.J. Knibbe; J.N. van den Anker, Co-promotores: H.P.A. van Dongen; B. van Ramshorst
Cytochrome P450 3A-mediated first-pass and systemic drug metabolism in children
From descriptive to physiological models that can predict oral absorption and elimination of CYP3A substrates across the pediatric age range.
Different medication dosage for morbidly obese patients
PhD research recently completed by pharmacologist Margreke Brill shows that morbidly obese patients should be given a different dosage of the drugs Cefazolin and Midazolam. This could also apply to other drugs such as anti-cancer drugs as well as antibiotics and Margreke Brill is advocating a change…
First-pass and systemic metabolism of cytochrome P450 3A substrates in neonates, infants, and children
Growth and development affect the metabolism of drugs administered to neonates, infants, and children.
24-hour rhythms in drug exposure and effect
Although rarely considered by the pharmaceutical industry or clinicians, 24-hour rhythms in physiology are a factor of potential influence on the pharmacokinetics and pharmacodynamics of drugs.
Key publications of the Quantitative Clinical Pharmacology group
PhD student Jantine Brussee wins second prize in PhD competition
PhD student of the division Pharmacology, Jantine Brussee has won the second prize of the Figon-Pfizer PhD student Competition, at the Dutch Medicine Days in Ede.
LACDR Spring Symposium